Cooper Companies (COO) Given a $282.00 Price Target by Oppenheimer Analysts

Oppenheimer set a $282.00 target price on Cooper Companies (NYSE:COO) in a research report released on Friday morning. The firm currently has a hold rating on the medical device company’s stock.

COO has been the topic of a number of other research reports. Zacks Investment Research upgraded Cooper Companies from a sell rating to a hold rating in a research note on Monday, October 1st. BMO Capital Markets raised their price objective on Cooper Companies from $294.00 to $306.00 and gave the stock an outperform rating in a research note on Friday. Wells Fargo & Co lifted their price target on Cooper Companies from $290.00 to $295.00 and gave the company an outperform rating in a research note on Monday, November 12th. ValuEngine upgraded Cooper Companies from a hold rating to a buy rating in a research note on Thursday, September 27th. Finally, Jefferies Financial Group lifted their price target on Cooper Companies to $305.00 and gave the company a buy rating in a research note on Friday. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Cooper Companies currently has a consensus rating of Buy and an average price target of $284.50.

Cooper Companies stock traded down $34.02 during mid-day trading on Friday, reaching $243.01. 1,253,678 shares of the company were exchanged, compared to its average volume of 333,174. Cooper Companies has a 12 month low of $216.47 and a 12 month high of $283.18. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.58 and a quick ratio of 1.54. The firm has a market cap of $13.61 billion, a PE ratio of 21.13, a price-to-earnings-growth ratio of 2.13 and a beta of 0.77.

Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, December 6th. The medical device company reported $2.87 EPS for the quarter, missing the Zacks’ consensus estimate of $2.96 by ($0.09). Cooper Companies had a return on equity of 17.86% and a net margin of 5.52%. The company had revenue of $651.50 million for the quarter, compared to the consensus estimate of $645.25 million. During the same quarter last year, the business earned $2.65 EPS. Cooper Companies’s revenue was up 16.0% on a year-over-year basis. Sell-side analysts expect that Cooper Companies will post 12.1 earnings per share for the current fiscal year.

In other news, Director A Thomas Bender sold 7,150 shares of Cooper Companies stock in a transaction on Monday, September 24th. The stock was sold at an average price of $269.36, for a total value of $1,925,924.00. Following the transaction, the director now owns 18,355 shares in the company, valued at approximately $4,944,102.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Allan E. Rubenstein sold 1,500 shares of Cooper Companies stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $265.37, for a total value of $398,055.00. Following the completion of the transaction, the director now owns 3,068 shares in the company, valued at approximately $814,155.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 20,691 shares of company stock worth $5,527,869. Corporate insiders own 1.60% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bradley Foster & Sargent Inc. CT boosted its holdings in shares of Cooper Companies by 10.1% during the 3rd quarter. Bradley Foster & Sargent Inc. CT now owns 2,184 shares of the medical device company’s stock valued at $605,000 after acquiring an additional 200 shares in the last quarter. Penserra Capital Management LLC boosted its holdings in shares of Cooper Companies by 16.5% during the 3rd quarter. Penserra Capital Management LLC now owns 1,564 shares of the medical device company’s stock valued at $433,000 after acquiring an additional 221 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Cooper Companies by 21.9% during the 3rd quarter. Mackenzie Financial Corp now owns 1,237 shares of the medical device company’s stock valued at $343,000 after acquiring an additional 222 shares in the last quarter. Bronfman E.L. Rothschild L.P. boosted its holdings in shares of Cooper Companies by 6.8% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,622 shares of the medical device company’s stock valued at $853,000 after acquiring an additional 232 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. boosted its holdings in shares of Cooper Companies by 1.3% during the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 19,770 shares of the medical device company’s stock valued at $4,655,000 after acquiring an additional 262 shares in the last quarter.

Cooper Companies Company Profile

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Story: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply